Skip to content

A Clinical Trial on the Improvement of Blood Parameters Using Different Oral Iron Dosages in Females with Iron Deficiency Anemia .

A Clinical Trial on the Improvement of Blood Parameters Using Different Oral Iron Dosages in Females with Iron Deficiency Anemia

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20251214068333N1
Enrollment
150
Registered
2026-01-19
Start date
2025-12-22
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron deficiency anemia. D50 Iron deficiency anaemia

Interventions

Intervention 1: Intervention group: Two 80 mg Duodenal Ferrofort capsules daily (160 mg). Intervention 2: Intervention group: One capsule of Ferrofort Duodenal 80 mg daily. Intervention 3: Interventio

Sponsors

Mazandaran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: diagnosis of Iron deficiency anemia using blood markers and ferritin testing by a hematology and adult cancer specialist informed consent to participate in the study hemoglobin lower than 12 or ferritin lower than 40 18 to 45 y.o ( before menopause) with out known underlying disease

Exclusion criteria

Exclusion criteria: lack of consent to participate in study and lack of cooperation in taking the oral Iron post menopausal women patient suspected or known to have inflammatory bowel disease celiac disease or known malabsorbtion syndrome history or current history of gastrointestinal cancer history of major intestinal or gastric resection surgeries current gastrointestinal bleeding history of previous total gastrectomy surgery treatment with oral or intravenous iron in the past 12 weeks use of new anticoagulant medication in the past 6 month plan for surgery_chemotherapy or blood transfusion in the next 12 week creatinin clearance less than 60 ml/min hemoglobin less than 9 with out concomitant thalassemia syndrome ( indication for injectable therapy) active bleeding history of underling liver,hear,or reumatological disease

Design outcomes

Primary

MeasureTime frame
CBC, Ferritin. Timepoint: Upon entering the study, months one, two, three. Method of measurement: The reference laboratory for conducting periodic tests will be the Tooba Clinic affiliated with Mazandaran University of Medical Sciences.

Secondary

MeasureTime frame
, Serum Iron, TIBC. Timepoint: Upon entering the study. Method of measurement: The reference laboratory for periodic tests will be Tooba Clinic affiliated with Mazandaran University of Medical Sciences.

Countries

Iran (Islamic Republic of)

Contacts

Public Contactjavad mozaffari

Mazandaran University of Medical Sciences

javadmozaffari2094@gmail.com+98 11 3335 0670

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026